NEUROCRINE Trademark

Trademark Overview


On Thursday, September 21, 2023, a trademark application was filed for NEUROCRINE with the United States Patent and Trademark Office. The USPTO has given the NEUROCRINE trademark a serial number of 98191100. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Friday, August 23, 2024. This trademark is owned by Neurocrine Biosciences, Inc.. The NEUROCRINE trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical preparations for human use for the treatment of endocrine, hormonal, and genetic diseases, disorders, and conditions; Pharmaceutical preparations for human use for the prevention and treatment of diseases, disorders, and conditions by gene therapy; Pharmaceutical preparations for human use for the prevention and treatment of diseases, disorders, and conditions by gene therapy, namely, Friedreich's ataxia, Parkinson's disease, GBA1-mediated diseases, and congenital birth defects; Pharmaceutical preparations for human use for the treatment of rare and orphan diseases, disorders, and conditions, namely, rare pediatric epilepsies, SCN8A developmental and epileptic encephalopathy, and congenital adrenal hyperplasia; Pharmaceutical preparations for human use for the treatment of Huntington's Disease, chorea associated with Huntington's Disease, schizophrenia, adjunctive treatment of schizophrenia, cognitive impairment associated with schizophrenia, epilepsy, epileptic encephal...

Providing medical information; Providing medical information in the field of endocrine, hormonal, and genetic diseases, disorders, and conditions; Providing medical information in the field of gene therapy; providing medical information in the field of psychiatric, neurological, central nervous system, and movement diseases, disorders, and conditions; Providing medical information in the field of Huntington's Disease and chorea associated with Huntington's Disease
neurocrine

General Information


Serial Number98191100
Word MarkNEUROCRINE
Filing DateThursday, September 21, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateFriday, August 23, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 18, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment of endocrine, hormonal, and genetic diseases, disorders, and conditions; Pharmaceutical preparations for human use for the prevention and treatment of diseases, disorders, and conditions by gene therapy; Pharmaceutical preparations for human use for the prevention and treatment of diseases, disorders, and conditions by gene therapy, namely, Friedreich's ataxia, Parkinson's disease, GBA1-mediated diseases, and congenital birth defects; Pharmaceutical preparations for human use for the treatment of rare and orphan diseases, disorders, and conditions, namely, rare pediatric epilepsies, SCN8A developmental and epileptic encephalopathy, and congenital adrenal hyperplasia; Pharmaceutical preparations for human use for the treatment of Huntington's Disease, chorea associated with Huntington's Disease, schizophrenia, adjunctive treatment of schizophrenia, cognitive impairment associated with schizophrenia, epilepsy, epileptic encephalopathy with continuous spike-and-wave during sleep, SCN8A-related epilepsy with encephalopathy, focal onset seizures, Parkinson's Disease, adjunctive treatment of Parkinson's Disease, Major Depressive Disorder, anhedonia in Major Depressive Disorder, inadequate response to treatment in Major Depressive Disorder, dyskinetic cerebral palsy, and neuro-immunological and neuroendocrinological diseases, disorders, and conditions
Goods and ServicesProviding medical information; Providing medical information in the field of endocrine, hormonal, and genetic diseases, disorders, and conditions; Providing medical information in the field of gene therapy; providing medical information in the field of psychiatric, neurological, central nervous system, and movement diseases, disorders, and conditions; Providing medical information in the field of Huntington's Disease and chorea associated with Huntington's Disease

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, October 8, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSunday, October 8, 2023
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNeurocrine Biosciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Party NameNeurocrine Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Trademark Events


Event DateEvent Description
Monday, September 25, 2023NEW APPLICATION ENTERED
Sunday, October 8, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, May 15, 2024ASSIGNED TO EXAMINER
Thursday, May 16, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 29, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 18, 2024PUBLISHED FOR OPPOSITION
Friday, August 23, 2024SOU EXTENSION 1 FILED
Tuesday, June 18, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 13, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, August 23, 2024SOU TEAS EXTENSION RECEIVED
Friday, August 23, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 23, 2024SOU EXTENSION 1 GRANTED
Tuesday, September 24, 2024TEAS STATEMENT OF USE RECEIVED
Tuesday, September 24, 2024TEAS REQUEST TO DIVIDE RECEIVED